How has been the historical performance of Aspira Pathlab?

Answer:The historical performance of Aspira Pathlab shows significant improvement from March 2024 to March 2025.

Breakdown:
In March 2025, Aspira Pathlab reported net sales of 22.00 Cr, a notable increase from 13.20 Cr in March 2024. Total operating income mirrored this growth, reaching 22.00 Cr compared to 13.20 Cr the previous year. The total expenditure, excluding depreciation, rose to 18.83 Cr from 14.76 Cr, primarily driven by higher raw material costs and employee expenses. Consequently, the operating profit (PBDIT) turned positive at 3.56 Cr, recovering from a loss of 1.14 Cr in the prior year. Profit before tax also improved significantly to 2.07 Cr from a loss of 2.67 Cr, leading to a profit after tax of 2.07 Cr, compared to a loss of 2.67 Cr in March 2024. The earnings per share (EPS) reflected this turnaround, increasing to 1.96 from a negative 2.59. The operating profit margin improved to 14.41%, up from -11.82%, while the profit after tax margin reached 9.18%, recovering from -20.23%. On the balance sheet, total assets increased to 17.46 Cr from 14.71 Cr, with shareholder's funds rising to 12.17 Cr from 10.14 Cr. The book value per share also improved to 7.03 from 5.07. Overall, Aspira Pathlab demonstrated a strong recovery and positive growth trajectory in its financial performance over the year.